Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.

Sun, Yongchang; Molins, Eduard; Daoud, Sami Z; Trivedi, Roopa; Stewart, Catherine; Lamarca, Rosa; Bharali, Pranob; Garcia-Gil, Esther

Sun, Yongchang; Molins, Eduard; Daoud, Sami Z; Trivedi, Roopa; Stewart, Catherine; Lamarca, Rosa; Bharali, Pranob; Garcia-Gil, Esther.

Affiliation

Sun Y; Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
Molins E; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Daoud SZ; Late Respiratory & Immunology, BioPharmaceuticals R&D, Gaithersburg, MD, USA. Electronic address: Sami.Daoud@astrazeneca.com.
Trivedi R; Late Respiratory & Immunology, BioPharmaceuticals R&D, Durham, NC, USA.
Stewart C; Statistics, Phastar, Chiswick, London, UK.
Lamarca R; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.
Bharali P; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Pvt. Ltd, Bangalore, India.
Garcia-Gil E; Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Barcelona, Spain.

Respir Med ; 218: 107393, 2023 11.

Article de En | MEDLINE | ID: mdl-37640273

Sujet(s)
Mots clés

Asia; Bronchodilation; Chronic obstructive pulmonary disease; Long-acting muscarinic antagonist; Long-acting ß(2)-agonist

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Bronchodilatateurs / Broncho-pneumopathie chronique obstructive Type d'étude: Clinical_trials Limites: Humans Langue: En Journal: Respir Med Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google